The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
09-Apr-24
Pending
Undisclosed
Target:
Tegra’s Operating Entities in Honduras, El Salvador, and the U.S.
Acquiror:
SAE-A Trading
Advising Tegra, a premier and leading near and onshore apparel manufacturer for sport, team, and performance apparel, on the sale of its operating entities in Honduras, El Salvador, and the U.S. to SAE-A Trading, a vertically integrated textile and apparel garment manufacturer
20-Feb-24
Pending
$185 million
Target:
myHomecare Group
Acquiror:
Australian Unity
Advising Australian Unity on its acquisition of myHomecare Group
10-Aug-23
Undisclosed
Target:
Clinigen Ltd’s portfolio of Established Medicines
Acquiror:
CNX Therapeutics
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
20-Jun-23
Pending
$595 million
Target:
Lookers Plc
Acquiror:
Alpha Auto Group
Advising JerseyCo, the indirect Holdco of Alpha Auto Group, a Canadian automotive dealership group, on its acquisition of Lookers Plc, a leading UK automotive dealership group
26-Apr-23
Pending
$127 million
Target:
Marley Spoon business combination with 468 SPAC II
Acquiror:
468 SPAC II SE
Advising Marley Spoon SE, an ASX listed global subscription-based meal kit provider, on its business combination agreement with 468 SPAC II, simultaneous capital raising and amendment to existing debt facilities
25-Apr-23
Pending
Undisclosed
Target:
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
Acquiror:
Advanz Pharma (UK)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
29-Mar-23
Undisclosed
Target:
Scandinavian Enviro Systems AB
Acquiror:
Antin Infrastructure Partners
Advising Enviro on the creation of the world’s first large-scale tire recycling group in a JV with Antin Infrastructure Partners, supported by Michelin
20-Mar-23
Pending
Undisclosed
Target:
Clinigen Ltd’s Lamda Laboratories
Acquiror:
Adragos Pharma
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
16-Feb-23
Pending
$220 million
Target:
Flavor Specialty Ingredients division of IFF
Acquiror:
Exponent Private Equity
Sole financial adviser to Exponent, one of the UK’s leading private equity firms, on the acquisition of IFF’s Flavor Specialty Ingredients division, a global leader in the base aromas market
23-Jan-23
Pending
$200 million
Target:
Clinigen Ltd’s Proleukin
Acquiror:
Iovance Biotherapeutics
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
24-Nov-22
Pending
Undisclosed
Target:
Kyowa Kirin International’s established medicines business
Acquiror:
Grünenthal
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
25-Oct-22
Pending
Undisclosed
Target:
Acreage Holdings
Acquiror:
Canopy Growth Corporation
Advising Canopy Growth, a leading diversified cannabis company, on the re-organization and consolidation of its U.S. cannabis assets under a new holding company, Canopy USA, and on related investments and debt repurchase transactions
11-Oct-22
Pending
$7.9 billion
Target:
Westinghouse Electric Company
Acquiror:
Brookfield Renewable Partners and Cameco
Advising the Independent Committee of Brookfield Renewable Partners, the flagship listed renewable power company of Brookfield Asset Management, in consortium with Cameco and other institutional partners, on the acquisition of Westinghouse Electric Company, one of the world’s largest nuclear services businesses, from Brookfield Business Partners
13-Sep-22
Undisclosed
Target:
InterGen N.V.’s UK business
Acquiror:
Bortela Capital s.r.o
Advised InterGen N.V., one of the UK’s largest independent power producers with a portfolio of four gas plants and a pipeline of large-scale battery energy storage system projects, on the sale of its business interests in the UK to CREDITAS Group, a Czech entity ultimately owned by Pavel Hubáček, whose energy division UCED is the fourth largest energy distributor in the Czech Republic
09-Aug-22
$1.2 billion
Target:
Recipe Unlimited Corporation
Acquiror:
Fairfax Financial Holdings
Advising the Special Committee of Recipe Unlimited, the largest full-service restaurant company in Canada, on its go private transaction with Fairfax Financial Holdings
08-Aug-22
Undisclosed
Target:
UK Operations of Lion Pty Limited
Acquiror:
Odyssey Inns Ltd
Advised Lion Pty Limited, one of Australasia’s leading beverage companies and a wholly owned subsidiary of Japanese conglomerate Kirin Holdings Co., Ltd., on the divestment of its UK operations to Odyssey Inns Ltd.
28-Jul-22
Pending
$1.6 billion
Target:
Derco Holdings
Acquiror:
Inchcape Plc
Advising and acting as sponsor to Inchcape plc, the leading independent global automotive distributor, on its proposed Class 1 acquisition of Derco, the largest independent automotive distributor by volume in Latin America
28-Mar-22
Pending
~$1.4 billion
Target:
Theramex
Acquiror:
Carlyle and PAI Partners
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
28-Mar-22
Pending
$105 million
Target:
Acacia Pharma Group plc
Acquiror:
Eagle Pharmaceuticals, Inc.
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
08-Dec-21
Pending
Undisclosed
Target:
Pet Circle
Acquiror:
Various global growth investors, including TDM Growth Partners, Prysm Capital, AirTree Ventures and Baillie Gifford
Advising Pet Circle, Australia’s leading online specialty pet company, on its unicorn Series C funding round, which included a A$125m primary capital raise
07-Dec-21
Pending
Undisclosed
Target:
Interamericana Trading Corporation and Simpson Motors
Acquiror:
Inchcape plc
Advising Inchcape plc, the leading independent global automotive distributor, on the acquisition of Interamericana Trading Corporation (“ITC”), a leading independent automotive distributor in the Caribbean region, and Simpson Motors, the leading automotive retailer in Barbados, from the Simpson Group
10-Nov-21
Undisclosed
Target:
Bell's Brewery
Acquiror:
Lion / Kirin
Advised Lion, one of Australasia’s leading beverage companies and a wholly owned subsidiary of Japanese conglomerate Kirin Holdings, on the acquisition of Bell’s Brewery, a leading US independent craft brewery
05-Oct-21
$175 million
Target:
Kao Data Ltd
Acquiror:
Infratil Ltd
Advised Kao Data Ltd, which is jointly owned by Legal & General Group PLC and Noé Group subsidiary Hockham, on raising an initial £120m-£130m growth capital commitment from Infratil Ltd with the objective of creating a £500m data centre platform
08-Sep-21
Undisclosed
Target:
Hydrogen Technology & Energy Corporation (HTEC)
Acquiror:
I Squared Capital
Advising I Squared Capital, an independent global infrastructure investment manager, on its acquisition of a 35% equity interest in HTEC, a privately-held leader in the hydrogen energy transition